Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087061 · ClinicalTrials.gov registry record · Phase 1
Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma
A Phase 1 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00087061: Completed Phase 1 study, sponsored by Jonsson Comprehensive Cancer Center.
NCT00087061 is a Phase 1 study that has completed, run by Jonsson Comprehensive Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00087061, a Phase 1 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy, such as gimatecan, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I/II trial is studying the side effects and best dose of gimatecan in treating patients with recurrent or progressive primary malignant glioma.
Interventions
- DRUG gimatecan
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-05 |
| Est. Completion | 2005-06 |
| Phase | Phase 1 |
What the finished NCT00087061 record still lists
NCT00087061 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which gimatecan is the first listed.
NCT00087061 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00087061 about?
NCT00087061 is a clinical study titled "Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma". RATIONALE: Drugs used in chemotherapy, such as gimatecan, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I/II trial is studying the side effects and best dose of gimatecan in treating patients with recurrent or progressive primary malignant...
What is the current status of trial NCT00087061?
This trial is currently completed. It is a Phase 1 study. The study started on 2004-05. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00087061?
The interventions under investigation include: gimatecan (DRUG).
Who is sponsoring clinical trial NCT00087061?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia